What does debt issuance cost amortization mean?

Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).

OnKure Therapeutics, Inc. OKUR Debt Issuance Cost Amortization

Inhibrx Biosciences, Inc.INBX

$732K+37.3%

Revenue-—

Operating income-$15.6M+8.1%

Net income-$15.2M+4.8%

EPS (diluted)-$1.11+6.7%

Cash & equivalents$192.1M+98.7%

Total debt$409.0K-57.2%

Total equity$184.4M+103%

Total assets$198.7M+98.9%

Operating cash flow-$12.9M+7.6%

CapEx$5.0K-72.2%

Free cash flow-$12.9M+7.7%

Market cap$184.2M+72.6%

Enterprise value-$7.49M-127%

Return on equity-42.7%—

Debt / equity0×0.0×

Current ratio13.8×+2.6×

Reported directly by OnKure Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: OnKure Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is OnKure Therapeutics, Inc.'s debt issuance cost amortization?: OnKure Therapeutics, Inc. (OKUR) reported debt issuance cost amortization of $14K in Q4 2024.
What does debt issuance cost amortization mean?: Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).